- Home
- JXG vs IBIO Comparison
JXG vs IBIO Comparison
Compare JXG & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JXG | IBIO |
|---|---|---|
| Founded | N/A | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9M | 16.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JXG | IBIO |
|---|---|---|
| Price | $7.61 | $1.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 376.6K | ★ 12.6M |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.26 | N/A |
| Revenue | ★ $46,835,624.00 | $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.11 |
| P/E Ratio | $1.40 | ★ N/A |
| Revenue Growth | 21.68 | ★ 185.71 |
| 52 Week Low | $3.01 | $0.56 |
| 52 Week High | $73.80 | $6.89 |
Technical Indicators
Market Signals| Indicator | JXG | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 86.09 | 57.50 |
| Support Level | $3.91 | $0.98 |
| Resistance Level | $9.00 | $3.82 |
| Average True Range (ATR) | 1.39 | 0.37 |
| MACD | 0.45 | 0.12 |
| Stochastic Oscillator | 79.72 | 32.57 |
Price Performance
Historical ComparisonAbout JXG JX Luxventure Limited Common Stock
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.